Welcome to our dedicated page for Alkermes Plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes Plc stock.
Alkermes plc (ALKS) is a leading neuroscience-focused biopharmaceutical company developing innovative therapies for central nervous system disorders. This page provides investors and industry observers with direct access to official company announcements, including regulatory milestones, clinical trial developments, and strategic business updates.
Our curated collection features Alkermes' latest press releases on FDA submissions, partnership agreements, and financial results. Users will find updates on key therapeutic areas such as schizophrenia treatments, narcolepsy research, and bipolar disorder therapies. The archive also includes manufacturing expansions and peer-reviewed study publications.
Bookmark this page for real-time updates on ALKS' neuroscience pipeline progress, quarterly earnings disclosures, and corporate governance announcements. Check regularly for new developments in the company’s clinical programs and commercial product portfolio.
Alkermes plc has completed the sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk for approximately $91 million. The sale is part of Alkermes' program to drive operational efficiency and align its infrastructure with business needs. The transaction includes a subcontracting agreement with Novo Nordisk until the end of 2025, expected to be cost-neutral to Alkermes. Post-subcontracting, the sale is anticipated to provide significant operating cost benefits and enhance profitability. Alkermes will retain royalty revenues from products manufactured at the facility while continuing to produce its commercial products in Ohio.
Alkermes plc reported first-quarter 2024 financial results with revenues of $350.4 million, GAAP net income of $38.9 million, and diluted GAAP earnings per share of $0.23. They reiterated their 2024 financial expectations. The company highlighted prescription growth for LYBALVI® and progress with ALKS 2680 for narcolepsy treatment. Key financial highlights include total revenues, profitability, revenue growth for LYBALVI, ARISTADAi, VIVITROL, and royalty revenues. Operating expenses saw an increase due to investments. The company's balance sheet showed cash and total investments of $807.8 million. Alkermes confirmed its financial expectations for 2024 and recent events like new board member appointments, data presentations, and study initiations.
FAQ
What is the current stock price of Alkermes Plc (ALKS)?
What is the market cap of Alkermes Plc (ALKS)?
